Literature DB >> 28387673

Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.

Beatriz García1,2, Carla Martín1,2, Olivia García-Suárez2,3, Bárbara Muñiz-Alonso1, Helena Ordiales1, Santiago Fernández-Menéndez4, Jorge Santos-Juanes5, Laura Lorente-Gea6, Sonia Castañón7, Ikerne Vicente-Etxenausia8, Kelvin Manuel Piña Batista9, Irune Ruiz-Díaz10, María Cristina Caballero-Martínez10,11, Jesús Merayo-Lloves2, Isabel Guerra-Merino6, Luis M Quirós1,2, Iván Fernández-Vega2,5,6,8.   

Abstract

BACKGROUND: Heparan sulfate proteoglycans (HSPGs) promote amyloid-β peptide and tau fibrillization in Alzheimer's disease (AD) and provide resistance against proteolytic breakdown. Heparanase (HPSE) is the only enzyme that cleaves heparan sulfate (HS). Heparanase 2 (HPSE2) lacks HS-degrading activity, although it is able to interact with HS with high affinity.
OBJECTIVE: To analyze HPSE and HPSE2 expressions at different stages of AD.
METHODS: RT-PCR was used to analyze transcription levels of both heparanases at different stages of AD, and immunohistochemistry was performed to localize each one in different parts of the brain.
RESULTS: Both proteins appeared overexpressed at different stages of AD. Immunohistochemistry indicated that the presence of the heparanases was related to AD pathology, with intracellular deposits found in degenerated neurons. At the extracellular level, HPSE was observed only in neuritic plaques with a fragmented core, while HPSE2 appeared in those with compact cores as well.
CONCLUSION: Given the involvement of HSPGs in AD pathology, there would seem to be a relationship between the regulation of heparanase expression, the features of the disease, and a possible therapeutic alternative.

Entities:  

Keywords:  Alzheimer’s disease; amyloid; amyloid-β; glycosaminoglycan; heparan sulfate; heparanase

Mesh:

Substances:

Year:  2017        PMID: 28387673     DOI: 10.3233/JAD-161298

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  10 in total

Review 1.  Heparan Sulfate Proteoglycans as Relays of Neuroinflammation.

Authors:  Paul O'Callaghan; Xiao Zhang; Jin-Ping Li
Journal:  J Histochem Cytochem       Date:  2018-01-01       Impact factor: 2.479

2.  Heparanome-Mediated Rescue of Oligodendrocyte Progenitor Quiescence following Inflammatory Demyelination.

Authors:  Darpan Saraswat; R Ross Welliver; Roopa Ravichandar; Ajai Tripathi; Jessie J Polanco; Jacqueline Broome; Edward Hurley; Ranjan Dutta; M Laura Feltri; Fraser J Sim
Journal:  J Neurosci       Date:  2021-01-20       Impact factor: 6.167

Review 3.  Glycosaminoglycans in Neurodegenerative Diseases.

Authors:  Weihua Jin; Fuming Zhang; Robert J Linhardt
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

4.  Heparanase overexpression impedes perivascular clearance of amyloid-β from murine brain: relevance to Alzheimer's disease.

Authors:  Xiao Zhang; Paul O'Callaghan; Honglian Li; Yingxia Tan; Ganlin Zhang; Uri Barash; Xiaomin Wang; Lars Lannfelt; Israel Vlodavsky; Ulf Lindahl; Jin-Ping Li
Journal:  Acta Neuropathol Commun       Date:  2021-05-10       Impact factor: 7.801

5.  Heparan sulfate proteoglycans as possible diagnostic molecular tools with therapeutic potential in Alzheimer´s disease.

Authors:  Iván Fernández-Vega; Laura Lorente-Gea; Carla Martín; Luis M Quirós
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

6.  Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder.

Authors:  Neil A Roberts; Emma N Hilton; Filipa M Lopes; Subir Singh; Michael J Randles; Natalie J Gardiner; Karl Chopra; Riccardo Coletta; Zunera Bajwa; Robert J Hall; Wyatt W Yue; Franz Schaefer; Stefanie Weber; Roger Henriksson; Helen M Stuart; Håkan Hedman; William G Newman; Adrian S Woolf
Journal:  Kidney Int       Date:  2019-03-08       Impact factor: 10.612

7.  Design and Synthesis of 6-O-Phosphorylated Heparan Sulfate Oligosaccharides to Inhibit Amyloid β Aggregation.

Authors:  Kenji Uchimura; Kazuchika Nishitsuji; Li-Ting Chiu; Takashi Ohgita; Hiroyuki Saito; Fabrice Allain; Veeranjaneyulu Gannedi; Chi-Huey Wong; Shang-Cheng Hung
Journal:  Chembiochem       Date:  2022-06-16       Impact factor: 3.461

8.  Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets.

Authors:  Laura Lorente-Gea; Beatriz García; Carla Martín; Luis M Quirós; Iván Fernández-Vega
Journal:  Neural Regen Res       Date:  2017-06       Impact factor: 5.135

Review 9.  Fibrotic Scar in Neurodegenerative Diseases.

Authors:  Nadia D'Ambrosi; Savina Apolloni
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

Review 10.  Basal lamina changes in neurodegenerative disorders.

Authors:  Benjamin Nguyen; Gregory Bix; Yao Yao
Journal:  Mol Neurodegener       Date:  2021-12-07       Impact factor: 14.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.